Skip to main content

Table 1 Patient demographic characteristics*

From: Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

  12 months 24 months 36 months
  Overall GA Overall GA Overall GA
N 35,312 12,144 21,927 7,386 14,315 4,693
Age       
≤18 0.6% 0.7% 0.7% 0.7% 0.8% 0.8%
19-35 22.4% 21.7% 21.1% 20.5% 19.2% 18.8%
36-50 50.2% 50.3% 51.5% 51.7% 52.3% 52.4%
51-62 24.2% 24.5% 24.5% 24.6% 25.6% 25.7%
≥63 2.6% 2.8% 2.3% 2.5% 2.2% 2.2%
Gender       
Female 76.5% 78.2% 76.7% 78.6% 76.6% 78.6%
  1. *Cohorts are subsets of one another.